Strong news, difficult markets: Why good results alone are not enough.
The second-quarter earnings season reached another peak last week, once again making it clear how demanding the current market environment remains. In addition to numerous corporate reports, investors also focused on the US Federal Reserve’s decision and geopolitical developments in the Middle East.
As expected, the US Federal Reserve left the key interest rate unchanged and reaffirmed its data-dependent course. At the same time, the future interest rate path remains open, as inflation and the economy continue to develop inconsistently. For capital markets, this means that both macroeconomic data and corporate earnings will continue to be closely monitored.
The geopolitical situation also remained tense. Despite some easing following the military conflict between Israel and Iran and US airstrikes on Iranian nuclear facilities, the Middle East remains a significant uncertainty factor for financial markets. The focus is on potential impacts on energy supply, oil prices, and global economic development. At the same time, rising defense spending worldwide supports the long-term prospects of companies in the security and defense sectors.
Against this backdrop, the earnings season once again showed how selectively capital markets are currently acting. Numerous companies impressed with strong operating results, yet price reactions varied significantly. While Amazon was able to gain significantly following convincing quarterly figures, Apple came under pressure despite the strongest June quarter in its corporate history. This confirmed once again that good results alone are often not enough on the stock market. Rather, the decisive factor is whether companies exceed the already high expectations of the market while simultaneously providing a convincing outlook for the coming quarters.
Development of the UMBRELLA Strategy
Strong results, mixed price reactions
The past week confirmed the UMBRELLA Strategy’s current focus on companies with structural growth drivers and high operational quality. At the same time, the example of Apple showed that strong corporate news does not necessarily lead to rising stock prices in the short term.
Apple presented the strongest June quarter in its corporate history. Growth was driven by robust demand for the iPhone, the Mac, and the high-margin services business. Despite the convincing operational development, the stock came under pressure after the figures were published. The decisive factor was less the results themselves than the already high expectations of the market.
Learn more: Apple Valuation Analysis
With the quarterly figures already published on July 24, NextEra Energy also confirmed the strength of its business model. Both the regulated utility business and activities in the renewable energy sector contributed to earnings growth. In the long term, the company continues to benefit from rising electricity demand, investments in grid infrastructure, and the expansion of data centers and AI infrastructure.
Learn more: NextEra Valuation Analysis
Defense sector remains a structural growth driver
Geopolitical tensions and rising defense spending worldwide continue to support the long-term prospects of European defense companies.
Rheinmetall impressed with preliminary quarterly figures that were above market expectations. Continued high demand for ammunition, military vehicles, and defense systems remained the most important growth driver. Although the stock reacted positively, it remained volatile following the previous correction. The focus increasingly shifted to operating cash flow and the timing of major customer payments. The full half-year report on August 6 should provide additional clarity on this.
Learn more: Preliminary Q2 figures from Rheinmetall
Within the UMBRELLA Strategy, Thales was newly added. The decisive factors were the strong half-year results as well as a new record order backlog. The defense and aerospace segments in particular contributed to growth and confirmed the persistently high structural demand for technologies in the areas of security, cybersecurity, and aerospace.
Learn more: Thales Valuation Analysis
Portfolio adjustments and healthcare sector in focus
Ahead of the quarterly figures on August 5, the position in MercadoLibre was further expanded. The company remains one of Latin America’s leading digital platforms, combining e-commerce, logistics, digital payment services, and financial services in an integrated ecosystem. The upcoming quarterly figures are considered an important catalyst for the further development of the position.
The healthcare sector remains the largest focus within the UMBRELLA Strategy. This is due to ongoing geopolitical uncertainties and the relatively defensive characteristics of many healthcare companies. At the same time, numerous companies in the sector possess attractive company-specific growth drivers.
Key positions include Revolution Medicines, Bayer, Eli Lilly, and Johnson & Johnson.
In this context, Revolution Medicines reached an important regulatory milestone. On July 22, 2026, the US FDA accepted the New Drug Application for daraxonrasib for the treatment of previously treated metastatic pancreatic cancer. This brought the company a decisive step closer to a potential first commercial product. The upcoming quarterly update should provide further information on the approval process and preparations for a potential market launch.
News from the Watchlist
Developments outside the current UMBRELLA Strategy also remained relevant.
Tesla was placed on the UMBRELLA Watchlist following the previous technical sell signal. The stock remained under pressure after the quarterly report. This shows that the market is currently paying closer attention to profitability, cash flow, and the costs of the company’s expansion plans.
There are also updates on the watchlist for Microsoft and Amazon via the valuation analyses. Especially for those who want to stay informed about these companies.
Outlook for the coming week
The earnings season now brings several important companies from the UMBRELLA Strategy and the watchlist into focus.
For Bayer, the focus is on the pharmaceutical and agricultural business, the outlook for the full year, and progress in managing legal risks.
For MercadoLibre, the focus is on the development of online retail, the digital payments business, and credit quality. Following the recent expansion of the position, the report will be crucial in determining whether the growth momentum remains intact.
An update on daraxonrasib and preparations for a potential market launch is expected from Revolution Medicines. For Eli Lilly, demand for Mounjaro and Zepbound, the expansion of production capacities, and progress in the drug pipeline remain the key topics.
The full report from Rheinmetall should provide further details on margins, cash flow, and production capacities following the strong preliminary figures.
Our focus remains on companies where strong fundamentals meet sustainable growth and clear long-term opportunities.
Stay up to date with the UMBRELLA Strategy. On MUMAK.me, you will regularly find our updates, valuation analyses, and market commentary on the companies we monitor and evaluate within the strategy.
Upcoming Events
| Date | Company | Event |
|---|---|---|
| August 4, 2026 | Bayer | Q2 2026 Figures |
| August 5, 2026 | MercadoLibre | Q2 2026 Figures |
| August 5, 2026 | Revolution Medicines | Q2 2026 Figures |
| August 5, 2026 | Eli Lilly | Q2 2026 Figures |
| August 6, 2026 | Rheinmetall | H1 2026 Figures |
